A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
Phase 4
Completed
NCT06229145
| Condition | Gout |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Amgen |
|---|
| Status | Completed |
|---|
| Enrollment | 262 participants |
|---|
| Interventions | Pegloticase, Methotrexate |
|---|
| Start date | Mar 18, 2024 |
|---|
| Completion date | Jul 30, 2025 |
|---|
| Results posted | Jul 1, 2026 |
|---|
Summary
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Month 6 (Weeks 20, 21, 22, 23, and 24) · percentage of participants
| Pegloticase 8mg Q2W + MTX | 70.8 percentage of participants |
|---|
| Pegloticase 16mg Q4W + MTX | 56.5 percentage of participants |
|---|
| p-value | 0.10 |
|---|
| Response rate difference | 12.7 (95% CI 1.2–24.1) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.